Explore more publications!
Jordan Technology Report
Got News to Share?

Jordan Technology Report: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Jordan Technology Report.

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

Press releases published on December 10, 2025

Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
December 10, 2025

Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
BitMart Reshapes the Copytrading Revenue Model: Introducing AUM-based Management Fees, Enabling Traders to Operate Like Fund Managers
December 10, 2025

BitMart Reshapes the Copytrading Revenue Model: Introducing AUM-based Management Fees, Enabling Traders to Operate Like Fund Managers

Indeterminate GlobeNewswire
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
December 10, 2025

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 10, 2025

Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO
December 10, 2025

NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO

Indeterminate GlobeNewswire
Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program
December 10, 2025

Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program

Indeterminate GlobeNewswire
Clearmind Medicine Announces 1-for-40 Reverse Share Split
December 10, 2025

Clearmind Medicine Announces 1-for-40 Reverse Share Split

Indeterminate GlobeNewswire
BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Kα Breaker, at the San Antonio Breast Cancer Symposium (SABCS)
December 10, 2025

BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Kα Breaker, at the San Antonio Breast Cancer Symposium (SABCS)

Indeterminate GlobeNewswire
Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome
December 10, 2025

Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome

Indeterminate GlobeNewswire
GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) 
December 10, 2025

GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) 

Indeterminate GlobeNewswire
Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025
December 10, 2025

Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025

Indeterminate GlobeNewswire
Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome
December 10, 2025

Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome

Indeterminate GlobeNewswire
Observe.AI named a Leader in the IDC MarketScape: AI-Enabled Contact Center Workforce Engagement Management 2025-2026 Vendor Assessment
December 10, 2025

Observe.AI named a Leader in the IDC MarketScape: AI-Enabled Contact Center Workforce Engagement Management 2025-2026 Vendor Assessment

Indeterminate GlobeNewswire
Four Points Technology Awarded a 2025 AWS Partner Award
December 10, 2025

Four Points Technology Awarded a 2025 AWS Partner Award

Indeterminate GlobeNewswire
IKIGAI Corporation Opens New Vietnam Headquarters, Advancing a Vision for Global Harmony and a Better World
December 10, 2025

IKIGAI Corporation Opens New Vietnam Headquarters, Advancing a Vision for Global Harmony and a Better World

Indeterminate GlobeNewswire
Pushpay Launches New AI Solutions, Turning Ministry Moments into Meaningful Action for the Church
December 10, 2025

Pushpay Launches New AI Solutions, Turning Ministry Moments into Meaningful Action for the Church

Indeterminate GlobeNewswire
MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach
December 10, 2025

MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach

Indeterminate GlobeNewswire
Photonic Sets New Standard with Distributed Quantum Resource Estimation
December 10, 2025

Photonic Sets New Standard with Distributed Quantum Resource Estimation

Indeterminate GlobeNewswire
Carrick Therapeutics Announces Positive Results from Phase 2 Randomized Trial of Samuraciclib in Combination with Fulvestrant in Patients with Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer
December 10, 2025

Carrick Therapeutics Announces Positive Results from Phase 2 Randomized Trial of Samuraciclib in Combination with Fulvestrant in Patients with Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer

Indeterminate GlobeNewswire
TP in Indonesia Launches TP.ai FAB, Driving the Future of Intelligent, Human-Centered Operations
December 10, 2025

TP in Indonesia Launches TP.ai FAB, Driving the Future of Intelligent, Human-Centered Operations

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions